Clinical Lymphoma Myeloma and Leukemia

Journal Information
ISSN / EISSN : 2152-2650 / 2152-2669
Published by: Elsevier BV (10.1016)
Total articles ≅ 6,846
Current Coverage
SCOPUS
SCIE
MEDICUS
MEDLINE
PUBMED
Archived in
SHERPA/ROMEO
Filter:

Latest articles in this journal

, Matthew Smith, Hua-Ling Tsai, Ravi Varadhan, Amy DeZern, , Christian Gocke, Jonathan Webster, Lukasz Gondek, Ivana Gojo, et al.
Clinical Lymphoma Myeloma and Leukemia; https://doi.org/10.1016/j.clml.2021.09.022

The publisher has not yet granted permission to display this abstract.
Enrique M. Ocio, Carmen Montes-Gaisán, Gabriela Bustamante, Sebastián Garzón, Esther González, , Maialen Sirvent, José María Arguiñano, Yolanda González, , et al.
Clinical Lymphoma Myeloma and Leukemia; https://doi.org/10.1016/j.clml.2021.10.001

The publisher has not yet granted permission to display this abstract.
, , Andrew H. Wei, Ignazia La Torre, Barry Skikne, Cl Beach, Valeria Santini
Clinical Lymphoma Myeloma and Leukemia; https://doi.org/10.1016/j.clml.2021.09.021

The publisher has not yet granted permission to display this abstract.
Chrysavgi Lalayanni, , Anastasia Athanasiadou, Michael Iskas, Maria Papathanasiou, Anastasia Marvaki, Sotiria Mpesikli, Giorgos Papaioannou, Despina Mallouri, Ioannis Batsis, et al.
Clinical Lymphoma Myeloma and Leukemia; https://doi.org/10.1016/j.clml.2021.09.019

The publisher has not yet granted permission to display this abstract.
Marina Moretti, Anna Marina Liberati, , Benedetta Puccini, , Guido Gini, Piero Galieni, , Maria Cantonetti, Vincenzo Pavone, et al.
Published: 29 September 2021
Clinical Lymphoma Myeloma and Leukemia; https://doi.org/10.1016/j.clml.2021.09.018

Abstract:
Background Patients with relapsed or refractory classical Hodgkin lymphoma (R/RcHL) have limited opportunities for a curative therapy. High-dose therapy followed by autologous stem cell transplantation (HDT-ASCT) produces cure rates of 50-60%. Patients relapsing after, or ineligible for HDT-ASCT have limited therapeutic options and long-term remission is uncommon. Furthermore, few patients are candidate to allogeneic stem cell transplantation (AlSCT), a potentially curative approach. The combination of brentuximab-vedotin and bendamustine (BVB) is a promising treatment for patients with R/RcHL, regardless of SCT eligibility. Patients and methods We report a real-life experience with BVB in 41 patients with R/RcHL after failure of ≥1 therapy including ASCT, AlSCT, or BV. Results Among 40 patients evaluable for efficacy, the overall response rate and complete response (CR) rate was 75% and 50%, respectively. No significant differences were observed between primary refractory and relapsed disease, previously treated with ≤2 and ≥3 lines of therapy, or BV-exposed and BV-naïve. After a median follow-up of 38 months, the median progression free survival (PFS) for the entire population is 26 months; PFS is not reached, 10.5 months and 4 months for patients achieving CR, partial response and no response, respectively (p<0,0001). BVB was well tolerated and no grade 4 toxicity or new safety signals were observed. The most common treatment-emergent adverse events were infections. Conclusion Our experience supports the efficacy and tolerability of the BVB combination in R/RcHL as a bridge to SCT or as a definitive therapy for SCT-ineligible patients. Larger comparative studies testing BVB against standards of care are warranted in both settings. MICROABSTRACT In the real-life setting, the combination of brentuximab vedotin and bendamustine was well tolerated and produced an ORR of 75%, CR 50% and a median PFS of 26 months. A significant proportion of heavily pretreated cHL patients may be cured with this approach.
Back to Top Top